In general, over-expression of p53 in cancer is attributed to a series of p53 mutations which either result in dominant-negative effects over wild-type p53, or, acquire new activities contributing to tumor progression and drug resistance [29, 10, 30, 31]. This evidence concerns the gene TP53 and cancer.